incrementalNew research

Weekly research monitor: 7 new sources added (2025-2026)

Schnitzler Syndrome →

Summary

Automated weekly search (2026-03-27) found 7 new publications not previously indexed. New entries include: AIDA Network real-world IL-1 data (K2), VEXAS vs Schnitzler differential markers (K3), neutrophil IL-1β source study (K4), NLRP3 mosaicism in urticarial lesions (K5), canakinumab in anakinra-refractory SchS (K6), paraprotein-negative Schnitzler-like syndrome update (K7), and Schnitzler+RA case (K8). No new clinical trials or preprints found. Baseline quality score: 79.7/100.

Related treatments

AnakinraIL-1 receptor antagonist
1st line~94%
CanakinumabAnti–IL-1β monoclonal antibody
2nd lineHigh (RCT confirmed)

Related genes

NLRP3Somatic mosaicism (various)
Found in patients with the most severe phenotypes. Demonstrates that NLRP3 can be directly causative in some cases.
NLRP3V198M
Found in 1 patient but 4 asymptomatic carriers across 3 generations — insufficient alone to cause disease.

More from Schnitzler Syndrome

incrementalNew research

Weekly research monitor: 4 new sources added (2025-2026)

significantTreatment update

AIDA Network real-world IL-1 inhibitor data: 60-month retention 64.7%

significantNew research

Neutrophils identified as predominant IL-1β source in SchS skin

incrementalGenetic finding

Low-level NLRP3 mosaicism extends Schnitzler phenotypic spectrum

ID: schnitzler-syndrome-update-8Type: new_researchImpact: incremental